Publications

Publications

 

  1. Li M, Sagastume EA, Lee D, McAlister D, DeGraffenreid AJ, Olewine KR, Graves SA, Copping R, Mirzadeh S, Zimmerman BE, Larsen RH, Johnson FL, & Schultz MK. (2020). Pb-203/Pb-212 Theranostic Radiopharmaceuticals for Image-Guided Radionuclide Therapy for Cancer. Current Medicinal Chemistry, 27, 1-29.
     

  2. Kunos CA, Mankoff DA, Schultz MK, Graves SA, Pryma DA. (2020). Radiopharmaceutical Chemistry and Drug Development — What’s Changed. Seminars in Radiation Oncology, In Press.
     

  3. Varmazyad M, Kalen AL, Sarsour E, Juan Du, Schultz MK, Pigge, FC, Goswami P. (2020) "N-alkyl triphenylvinylpyridinium conjugated dihydroartemisinin perturbs mitochondrial functions resulting in enhanced cancer versus normal cell toxicity. Journal of Medicinal Chemistry, jm-2020-014257, In Review.
     

  4. Kloepping KC, Kraus AS, Hedlund DK, Gnade CM, Wagner BA, McCormick ML, Fath MA, Seol D, Lim TH, Buettner GR, Goswami PC, Pigge FC, Spitz DR, & Schultz MK. (2020) Triphenylphosphonium derivatives disrupt metabolism and inhibit melanoma growth in vivo when delivered via a thermosensitive hydrogel. PLoS One. In review.
     

  5. Falls-Hubert KC, Butler A, Gui K, Anderson M, Li M, Stolwijk JM, Rodman III SN, Solst SR, Tomanek-Chalkley A, Searby CC, Sheffield VC, Sandfort V, Schmidt H, McCormick M, Wels BR, Allen BG, Buettner GR, Schultz MK, & Spitz DR. (2020). Disulfiram causes selective hypoxic cancer cell toxicity and radio-chemo-sensitization via redox cycling of copper. Free Radical Biology and Medicine, 150; 1-11.
     

  6. Li M, Lee D, Liu D, Quinn TP, Sagastume EA, Mott S, Gibsen-Corley KN, Johnson FL, & Schultz MK. (2019) MAPK and HDAC Inhibitors Sensitize Malignant Melanoma to Alpha-particle Radiation Targeting Melanocortin Subtype 1 Receptor (MC1R). Molecular Pharmaceutics., Jul 31. 16 (9), 3904-3915. PMID 31318566.
     

  7. Lee D, Li M, Bednarz B, & Schultz MK. (2018) Modeling cell and tumor-metastasis dosimetry with the Particle and Heavy Ion Transport code System (PHITS) software for targeted alpha-particle radionuclide therapy. Radiation Research., 2018 Sep;190(3):236-247. PMID:29944461.

  8. Ghai A, Singh B, Li M, Daniels TA, Coelho R, Orcutt K, Watkins GL, Norenberg JP, Cvet D, and Schultz MK. (2018). Optimizing the radiosynthesis of [68Ga]DOTA-MLN6907 peptide containing three disulfide cyclization bonds – a GCC specific chelate for clinical radiopharmaceuticals. Appl Rad Isot., Volume 140, October 2018, pages 333-341.
     

  9. Menda Y, Madsen MT, O'Dorisio TM, Sunderland J, Watkins LG, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS. (2018). 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine. 2018 Nov;59(11):1692-1698. PMID: 29523629.
     

  10. Vanneste M, Huang Q, Li M, Moose D, Zhao L, Stamnes M, Schultz MK, Wu M, Henry M. (2018) High content screening identifies monensin as an EMT-selective cytotoxic compound. Scientific Reports. 2019; 9: 1200.
     

  11. May D, Nelson AN, & Schultz MK. Quantitation of lead-210 (Pb-210) using lead-203 (Pb-203) as a "Massless" yield tracer. J Environ Radioact. 2017 May;171:93-98. doi: 10.1016/j.jenvrad.2017.02.003. Epub 2017 Feb 16.
     

  12. Menda Y, O'Dorisio TM, Howe JR, Schultz MK, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O'Dorisio MS. (2017) Localization of Unknown Primary Site with [68Ga]DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. Journal of Nuclear Medicine. 2017 Jul;58(7):1054-1057. PMCID: PMC5493006.
     

  13. Li M, Zhang X, Quinn TP, Lee D, Liu D, Kunkel F, Zimmerman BE, McAlister D, Olewine K, Menda Y, Mirzadeh S, Copping R, Sagastume, Johnson FL, & Schultz MK. (2017) Production of high specific activity [203/212-Pb]DOTA-conjugated radiopharmaceuticals for clinical image-guided radionuclide cancer therapy using an automated cassette-based system. Applied Radiation and Isotopes. 2017;May 10;127:52-60. PMID: 28521118.
     

  14. Schoenfeld, JD, Sibenaller, ZA, Cramer-Morales, KL, Mapuskar, KA, Wagner, BA, Sandhu, S, Carlisle, TL, Smith, MC, Abu Hejleh, T, Furqan, M, Berg, DJ, Zhang, J, Keech, J, Parekh, KR, Bhatia, S, Bodekar, KL, Ahmann, L, Vollstedt, S, Brown, H, Shanahan-Kauffman, EP, Schall, ME, Hohl, RJ, Clamon, GH, Smith, B, Greenlee, JD, Howard, MA, Monda, V, Riley, DP, Schultz, MK, Domann, FE, Cullen, JJ, Buettner, GR, Buatti, JM, Spitz, DR, Allen, BG. (2017). O2·- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of Lung and Brain Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 31(4); 487–500.
     

  15. Rosenblum J, Nelson AW, Schultz MK, Ryan J, Linden K. (2017) Temporal characterization of flowback and produced water quality from a hydraulically fractured oil and gas well". Science of the Total Environment, Oct 15;596-597:369-377..
     

  16. Knight AW, Qiao B, Ferru G, Forbes TZ, Schultz MK, Ellis R (2016) Do Aliphatic Alcohols Behave as Surfactants in Dodecane-Water Systems?" Langmuir, In Press (June).
     

  17. Reedy JL, Gabr MT, Hedlund DK, Pigge FC, & Schultz MK (2016). Synthesis and evaluation of mitochondrial-targeted triphenylvinylpyridine (TPVP) derivatives for the treatment of metastatic melanoma. Bioconjugate Chemistry,27(10):2424-30.
     

  18. Schibler J, Tomanek-Chalkley AM, Reedy JL, Zhan F, Spitz DR, & Schultz MK, Goel A (2016). Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells. PLoS One, 11(11).
     

  19. Knight AW, Eitrheim ES, Peterson MC, Nelson AW, McAlister D, Forbes TZ, & Schultz MK (2016). Efficient-selective separation of protactinium from complex mixed actinide matrices via aliphatic alcohols: Inferred speciation under acidic conditions. Solvent Extraction and Ion Exchange; Issue 5; Volume 34.
     

  20. Nelson AW, Knight AW, May D, Eitrheim ES, & Schultz MK. (2016). Naturally-Occurring Radioactive Materials (NORM) Associated with Unconventional Drilling for Shale Gas. In Drogos, D.L. (Ed.), Hydraulic Fracturing: Environmental Issues (pp. 89-128). Washington DC: American Chemical Society.
     

  21. Mueller D, Breeman WAP, Klette I, Gottschald A, Odparlik A, Baehre M, Tworowska I, & Schultz MK (2016). Radiolabeling of DOTA-like conjugated peptides with generator-produced 68Ga and using NaCl based cationic elution method. Nature Protocols. 11, 1057–1066 (2016).
     

 

Abstracts, Posters, and Oral Presentations
 

  1. Li M, Lee D, Liu D, Graves S, Bushnell D, Menda Y, O’Dorisio MS, & Schultz MK (2020). Enhancing tumor-specific immune response by combining immune checkpoint inhibitors with receptor targeted radionuclide therapy for metastatic melanoma. Invited presentation. Evolving Targeted Therapies for Cancer Workshop – Sponsored by the US National Isotopes Development Center, US Department of Energy.
     

  2. Schultz MK and Li M. (2020) Optimizing peptide and chelator structure for receptor targeted alpha particle therapy for SST2R positive cancers. Invited presentation. Evolving Targeted Therapies for Cancer Workshop – Sponsored by the US National Isotopes Development Center, US Department of Energy. 
     

  3. Schultz MK (2019). Pb-212-/Pb-203 Theranostics for Cancer. Invited presentation. Theranostics World Congress. Jeju, South Korea, March
    1-4, 2019.

     

  4. Lee D, Li M, Liu D, Kapoor S, Prindle J, Smith A, Schultz MK. Enhancing efficacy of PRRT for neuroendocrine tumors by combining with everolimus and histone deacetylase inhibitors. 2018 North American Neuroendocrine Tumor Symposium (poster selected for oral presentation). Seattle; October 4-6, 2018
     

  5. Lee D, Li M, Liu D, Schultz MK. Long-term renal toxicity of Pb-212-DOTA-tyr3-octreotide for treatment of neuroendocrine tumors and protection with a megalin antisense oligonucleotide. 2018 Central States chapter of Society of Toxicology (Poster presentation; outstanding poster award). Manhattan KS; October 18-19, 2018
     

  6. Lee D, Li M, Liu D, Kapoor S, Prindle J, Smith A, Schultz MK. Enhancing SSTR2-targeted alpha particle therapy for neuroendocrine tumors with everolimus and histone deacetylase inhibitors. 2019 Theranostics World Congress (poster selected for oral presentation). Jeju, South Korea; March 1-3.
     

  7. Schultz MK (2018). Pb-212/Pb-203 Theranostics for Image-Guided Alpha Particle Therapy for Cancer. Invited presentation. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. Philadelphia PA, June 24th, 2018.
     

  8. Schultz MK (2018). Pediatric Imaging Council. Invited presentation. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. Theranostics for Pediatric Brain Tumors: Medulloblastoma. Philadelphia PA, June 25th, 2018.
     

  9. Schultz MK (2017). World Molecular Imaging Congress. Targeted radionuclide therapy for metastatic melanoma. Bridging academia and industry. Invited presentation. World Molecular Imaging Society. Philidelphia, PA USA; September 17-19.
     

  10. Schultz MK. (2016). World Molecular Imaging Society: Annual Translational Molecular Imaging Symposium; Invited presentation. Image-Guided Therapy for Metastatic Melanoma; Boston, MA (May 12).
     

  11. Li M, Lee D, Liu D, Kapoor S, & Schultz MK (2018). Preclinical evaluation of M7-PSC, a click-cyclized alpha-MSH analogue conjugated with a bivalent metal-specific chelator (PSC). World Molecular Imaging Congress, Seattle WA, Sept. 12-16; Late breaking abstract/poster.
     

  12. Kapoor S, Li M, Lee D, Liu D, Johnson FL, & Schultz MK. Redox Imbalance Mediates Adaptation to MAPKi via ER Stress and Autophagy in Melanoma (2017). World Congress on Melanoma/Society for Melanoma Research October 21-25, 2018, Brisbane, Australia (oral presentation).
     

  13. Liu D, Li M, Bellizzi AM, Menda Y, Lee D, Nourmahnad K, Ghobrial SN, Schultz MK, O’Dorisio MS. Preclinical evaluation of CXCR4 as novel radio-theranostic target for high grade neuroendocrine and neuroblastoma tumors. Society of Nuclear Medicine and Molecular Imaging, Phillidelphia, PA. June 23-26. Abstract. 
     

  14. Schultz MK. The role of the academic entrepreneur in advancing imaging science. Invited “Spotlight” Presentation. World Molecular Imaging Society Annual Meeting, Sept 15, 2017.
     

  15. Schultz MK. The role of the academic entrepreneur in technology transfer and university startup companies: The E-Myth and True Grit. Invited Presentation. Washington University in St. Louis, May 23, 2017.
     

  16. Hernandez-Vargas S, Ghosh SC, Voss J, Lee D, Schultz MK, Azhdarinia A. (2017). Synthesis and characterization of a 68Ga/NIR labeled peptide for somatostatin receptor targeting. Accepted for oral presentation at the Annual Meeting of the Society of Nuclear Medicine, Denver, CO, June 10-14, 2017.
     

  17. Li M, Lee D, & Schultz MK. (2017). Preparation of high specific activity Pb-203 and Pb-212 labeled peptides using an automated system. International Society of Radiopharmaceutical Sciences Meeting. Dresden, Germany. May, 2017.
     

  18. Okoye, N., Rold, T.L., Berendzen, A.F., Zhang, X., White, R. M., Schultz, MK, Li, M., Dresser, T.P., Jurisson, S.S., Quinn, T.P., and Hoffman, T.J. (2017). Targeting the BB2 receptor in prostate cancer using a Pb-203 labeled peptide. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. Denver, CO (June, 2017).
     

  19. Tworowska I, Wagh N, Thamake S, Schultz MK, Delpassand ES (2017). 64Cu-labeled dimeric glucosamine conjugates and their evaluation in metastatic melanoma- cancer cells. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. Denver, CO (June, 2017)
     

  20. Okoye N, Schultz MK, Jurisson S, Hoffman T. (2017). Purification of cyclotron-produced 203PbCl2 and synthesis of a 203Pb labeled peptide. Northeast/Midwest NOBCChE Regional Conference (http://www.nexm2017.chem.pitt.edu/).
     

  21. Schultz MK. Image-guided Receptor-targeted Radionuclide Therapy for Metastatic Melanoma (2017). Invited presentation; University of Missouri, Columbia; April 26th, 2017.
     

  22. Li M, Lee D, Kapoor S, Liu D, & Schultz MK. (2017) Enhanced efficacy of image-guided targeted α-particle therapy for human metastatic melanoma by co-treatment of MAPK and HDAC inhibitors. Society for Melanoma Research Congress, Boston MA, Nov. 6-9; Abstract.
     

  23. Kapoor S, Li M, Lee D, Liu D, Johnson FL, & Schultz MK. (2017) BRAFi induced thiol imbalance leads to BRAFi adaptation via autophagic flux. Society for Melanoma Research Congress, Boston MA, Nov. 6-9; Abstract.
     

  24. Schultz MK. Image-guided Receptor-targeted Radionuclide Therapy for Metastatic Melanoma (2016).  World Molecular Imaging Society 2016 Translational Imaging Symposium, Boston, MA.
     

  25. Knight, A. W., Eitrheim, E. S., Nelson, A. W., & Schultz, M. K. (2014). Inferred Pa(V) Complex formation via Selective Extraction by Aliphatic Alcohols. Radiobioassay and Radiochemical Measurements Conference, Knoxville, TN, 29 October 2014.